Accordingly, CREB activation ameliorates synaptic and memory deficits in APP transgenic mice (Smith et al., 2009; Yiu et al., 2011), whereas CRTC1 gene therapy reverses early transcriptional changes and memory impairments in AD mice (Parra-Damas et al., 2014). Here, APP is linked to Alzheimer disease.